Vaxart Inc (NASDAQ:VXRT) is trading higher Thursday morning after the company announced that it has shown, for the first time in clinical trials, that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier.
"These results are very important because they support our belief that our oral tablet vaccines have the potential to be used repeatedly for indications that may require an annual boost, such as flu, COVID-19, or norovirus," said Andrei Floroiu, CEO of Vaxart.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The data came from Vaxart's 12-subject Phase 1b blinded study.
Vaxart is a clinical-stage biotechnology company focused on developing oral vaccines that are administered via tablet as opposed to injection.
Price Action: Vaxart has traded as high as $24.90 and as low as $3.50 over a 52-week period.
At last check Thursday, the stock was up 12.20% at $9.21.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.